FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102034262> ?p ?o ?g. }

• W2102034262 endingPage "300" @default.
• W2102034262 startingPage "298" @default.
• W2102034262 abstract "The diastole is the phase of the cardiac cycle in which the ventricles fill with the blood deriving from the atria, ready to be pumped into the pulmonary or peripheral circulation during systole. The initial phase of the diastole is the myocardial relaxation, in which calcium reuptake in the sarcoplasmic reticulum and the release of the actin-myosin bonds allow for an energy-dependent elongation of the fibers allowing for a pressure gradient-dependent flow of blood from the atria to the ventricle. Abnormalities in the myocardial relaxation delay the rate of ventricular pressure decline leading to delayed opening of the atrioventricular valves, which, due to the gradual increase in atrial pressure, occurs at a higher value of ventricular pressure, and rapid equalization of the pressure limiting the gradient and limiting early ventricular filling. Late ventricular filling on the other hand is more dependent on the elastic properties of the ventricle (elastance=1/compliance). A hypertrophic or fibrotic left ventricle will oppose more resistance to filling, and thus impairs late ventricular filling. Impairment in the myocardial relaxation and/or of the ventricular compliance determines the presence of diastolic dysfunction. Diastolic dysfunction in the heart may occur as a result of normal ageing, but it more often is caused by metabolic or structural abnormalities in the myocardium, which are the substrate for diastolic heart failure (or heart failure with preserved ejection fraction – HFpEF) (Borlaug 2014). The pathophysiology of diastolic dysfunction and heart failure is poorly understood. In particular, it is not clear how acute metabolic changes, such as ischaemia, hypoxia or inflammation, cause impairment in myocardial relaxation (Butler et al. 2014). In this issue of Acta Physiologica, Hillestad and colleagues shed light on this field, by showing that Interleukin-18 (IL-18) mediates diastolic dysfunction secondary to ambient (alveolar) hypoxia in the mouse (Hillestad et al. 2014) (Fig. 1). Hypoxia to the heart may occur in the setting of a significant reduction of blood flow, which can be regional (ischaemia) or global (shock), or it may occur when low oxygen tension is found in the alveoli such as in the setting of high altitude (ambient hypoxia), chronic lung diseases or acute inflammation or infection of the lungs. Independent of the cause of hypoxia, the cellular stress response is activated and in the heart leads to impaired diastolic function. In this study, mice were exposed to chronic ambient hypoxia to artificially diminish oxygen tension. They found that the left ventricular relaxation time constant, Tau, and the isovolumetric relaxation time (IVRT) were increased following hypoxia, indicating diastolic dysfunction due to impaired myocardial relaxation. Using the same mouse model, the same research group had previously shown that plasma levels of IL-18 are increased during hypoxia (Larsen et al. 2008). They now show that the treatment with IL-18 binding protein (IL-18 BP) during hypoxia restores diastolic function, normalizing Tau and the IVRT. At a molecular level, chronic hypoxia reduced phosphorylation of phospholamban (PLN) in the heart (Larsen et al. 2008, Hillestad et al. 2014). PLN is a key regulator of the intracellular calcium level; therefore, changes in its activity alter both contraction and relaxation. Treatment with IL-18 BP normalized PLN phosphorylation, a finding that contributes to explain the recovery of diastolic function in the IL-18 BP-treated mice. Finally, no changes were observed in the collagen production. This is particularly important because it suggests that the pathophysiological activity of IL-18 in this model mostly affects the active phases of the diastole and not the compliance of the ventricle. IL-18 is a pro-inflammatory cytokine of the IL-1 family (Dinarello et al. 2013). It is released by leucocytes upon the formation of an active inflammasome and signals through a single membrane receptor (Dinarello et al. 2013). An association between IL-18 and heart disease has been proposed by clinical studies linking higher levels of IL-18 with increased risk of acute myocardial infarction, heart failure and cardiac death (O'Brien et al. 2014). Experimental animal models have clearly shown that IL-18 is produced in the heart, also by cardiomyocytes, and also has very specific effects affecting cardiomyocyte function in vitro and in vivo (O'Brien et al. 2014). IL-18 induces hypertrophy of cardiomyocytes and impairs the systolic function (O'Brien et al. 2014, Toldo et al. 2014). Daily injections of IL-18 impaired diastolic function in the mouse heart, inhibiting myocardial relaxation, probably through an effect on the intracellular calcium transients (Woldbaek et al. 2005). Prolonged treatment with IL-18 also induces a phenotype of HFpEF in which impaired diastolic function is associated with elevated LV filling pressures, LV hypertrophy and interstitial fibrosis (Woldbaek et al. 2005, Platis et al. 2008). Experimental data also suggest that IL-18 has negative effects on the heart following myocardial ischaemia and in acute myocarditis (O'Brien et al. 2014). Hillestad and colleagues now not only confirm the central role of IL-18 in a model of hypoxia in the mouse, and the effects on PLN (Larsen et al. 2008), but also identify in IL-18 BP a potentially clinically valuable strategy. Recombinant human IL-18 BP is already being tested in phase II clinical trials (Dinarello et al., 2013; O'Brien et al. 2014). The clinical relevance of the new data presented is therefore large. IL-18 may provide the elusive link between metabolic derangements, that is, hypoxia, and cardiac diastolic dysfunction. There is a clear association between chronic obstructive pulmonary disease and diastolic dysfunction (Funk et al. 2008), and a strategy of IL-18 blockade may prove valuable in both limiting lung injury as well as restoring cardiac diastolic function. Moreover, the large pre-clinical evidence linking IL-18 and heart failure suggests that a strategy of IL-18 blockade may be valuable also in heart failure unrelated to pulmonary disease. In this regard, the prevalence of HFpEF is growing exponentially and contrary to systolic heart failure, there are no current therapeutic strategies proven efficacious for the treatment of diastolic heart failure. Testing IL-18 blockade in other models of diastolic dysfunction will help to understand whether this strategy may be effective to treat diastolic dysfunction and HFpEF beyond the dysfunction associated with hypoxia. Dr. Toldo is supported by an American Heart Association Post-Doctoral Grant. During the last 36 months, Dr. Abbate has received research grants from Novartis (Basel, Switzerland) and AB2 Bio (Losanne, Switzerland)." @default.
• W2102034262 created "2016-06-24" @default.
• W2102034262 creator A5049273996 @default.
• W2102034262 creator A5080976772 @default.
• W2102034262 date "2014-10-24" @default.
• W2102034262 modified "2023-10-16" @default.
• W2102034262 title "Diastolic dysfunction in chronic hypoxia: IL-18 provides the elusive link" @default.
• W2102034262 cites W1566050849 @default.
• W2102034262 cites W1880552130 @default.
• W2102034262 cites W1967272371 @default.
• W2102034262 cites W1991611246 @default.
• W2102034262 cites W2031691104 @default.
• W2102034262 cites W2057547167 @default.
• W2102034262 cites W2064856766 @default.
• W2102034262 cites W2100108710 @default.
• W2102034262 cites W2134827458 @default.
• W2102034262 doi "https://doi.org/10.1111/apha.12403" @default.
• W2102034262 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25293945" @default.
• W2102034262 hasPublicationYear "2014" @default.
• W2102034262 type Work @default.
• W2102034262 sameAs 2102034262 @default.
• W2102034262 citedByCount "1" @default.
• W2102034262 countsByYear W21020342622017 @default.
• W2102034262 crossrefType "journal-article" @default.
• W2102034262 hasAuthorship W2102034262A5049273996 @default.
• W2102034262 hasAuthorship W2102034262A5080976772 @default.
• W2102034262 hasBestOaLocation W21020342621 @default.
• W2102034262 hasConcept C126322002 @default.
• W2102034262 hasConcept C164705383 @default.
• W2102034262 hasConcept C178790620 @default.
• W2102034262 hasConcept C185592680 @default.
• W2102034262 hasConcept C540031477 @default.
• W2102034262 hasConcept C57900726 @default.
• W2102034262 hasConcept C71924100 @default.
• W2102034262 hasConcept C7836513 @default.
• W2102034262 hasConcept C84393581 @default.
• W2102034262 hasConceptScore W2102034262C126322002 @default.
• W2102034262 hasConceptScore W2102034262C164705383 @default.
• W2102034262 hasConceptScore W2102034262C178790620 @default.
• W2102034262 hasConceptScore W2102034262C185592680 @default.
• W2102034262 hasConceptScore W2102034262C540031477 @default.
• W2102034262 hasConceptScore W2102034262C57900726 @default.
• W2102034262 hasConceptScore W2102034262C71924100 @default.
• W2102034262 hasConceptScore W2102034262C7836513 @default.
• W2102034262 hasConceptScore W2102034262C84393581 @default.
• W2102034262 hasFunder F4320306230 @default.
• W2102034262 hasIssue "2" @default.
• W2102034262 hasLocation W21020342621 @default.
• W2102034262 hasLocation W21020342622 @default.
• W2102034262 hasOpenAccess W2102034262 @default.
• W2102034262 hasPrimaryLocation W21020342621 @default.
• W2102034262 hasRelatedWork W2008851126 @default.
• W2102034262 hasRelatedWork W2011347913 @default.
• W2102034262 hasRelatedWork W2049397185 @default.
• W2102034262 hasRelatedWork W2073151595 @default.
• W2102034262 hasRelatedWork W2074833529 @default.
• W2102034262 hasRelatedWork W2125804349 @default.
• W2102034262 hasRelatedWork W2159512267 @default.
• W2102034262 hasRelatedWork W2304633692 @default.
• W2102034262 hasRelatedWork W2355498105 @default.
• W2102034262 hasRelatedWork W2399063111 @default.
• W2102034262 hasVolume "213" @default.
• W2102034262 isParatext "false" @default.
• W2102034262 isRetracted "false" @default.
• W2102034262 magId "2102034262" @default.
• W2102034262 workType "article" @default.